| 2026-08-31 |
Arch Biopartners Inc. |
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide archbiopartners.com ↗ |
| 2026-04-30 |
Arch Biopartners Inc. |
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI archbiopartners.com ↗ |
| 2026-03-20 |
Arch Biopartners Inc. |
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide archbiopartners.com ↗ |
| 2025-12-16 |
Arch Biopartners Inc. |
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide archbiopartners.com ↗ |
| 2025-08-06 |
Arch Biopartners Inc. |
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury archbiopartners.com ↗ |
| 2025-04-22 |
Arch Biopartners Inc. |
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) archbiopartners.com ↗ |
| 2025-01-08 |
Arch Biopartners Inc. |
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) archbiopartners.com ↗ |
| 2024-11-11 |
Arch Biopartners Inc. |
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-09-11 |
Arch Biopartners Inc. |
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) archbiopartners.com ↗ |
| 2024-06-18 |
Arch Biopartners Inc. |
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) archbiopartners.com ↗ |
| 2024-04-16 |
Arch Biopartners Inc. |
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-04-03 |
Arch Biopartners Inc. |
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-04-02 |
Arch Biopartners Inc. |
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-03-18 |
Arch Biopartners Inc. |
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2 archbiopartners.com ↗ |
| 2024-03-15 |
Arch Biopartners Inc. |
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-03-07 |
Arch Biopartners Inc. |
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-01-10 |
Arch Biopartners Inc. |
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2024-01-03 |
Arch Biopartners Inc. |
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury archbiopartners.com ↗ |
| 2023-12-21 |
Arch Biopartners Inc. |
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide archbiopartners.com ↗ |
| 2023-12-13 |
Arch Biopartners Inc. |
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide archbiopartners.com ↗ |
| 2023-09-22 |
Arch Biopartners Inc. |
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide archbiopartners.com ↗ |
| 2023-04-18 |
Arch Biopartners Inc. |
Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide archbiopartners.com ↗ |
| 2023-03-23 |
Arch Biopartners Inc. |
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program archbiopartners.com ↗ |
| 2022-02-14 |
Arch Biopartners Inc. |
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok) archbiopartners.com ↗ |
| 2022-02-03 |
Arch Biopartners Inc. |
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury archbiopartners.com ↗ |
| 2022-01-04 |
Arch Biopartners Inc. |
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok) archbiopartners.com ↗ |
| 2021-12-01 |
Arch Biopartners Inc. |
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial archbiopartners.com ↗ |
| 2021-08-05 |
Arch Biopartners Inc. |
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide archbiopartners.com ↗ |
| 2021-07-14 |
Arch Biopartners Inc. |
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease archbiopartners.com ↗ |
| 2021-05-04 |
Arch Biopartners Inc. |
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19 archbiopartners.com ↗ |
| 2021-03-30 |
Arch Biopartners Inc. |
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide archbiopartners.com ↗ |
| 2021-03-16 |
Arch Biopartners Inc. |
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide archbiopartners.com ↗ |
| 2021-02-26 |
Arch Biopartners Inc. |
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients archbiopartners.com ↗ |
| 2021-02-02 |
Arch Biopartners Inc. |
Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide archbiopartners.com ↗ |
| 2021-01-05 |
Arch Biopartners Inc. |
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients archbiopartners.com ↗ |
| 2020-12-10 |
Arch Biopartners Inc. |
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients archbiopartners.com ↗ |
| 2020-11-05 |
Arch Biopartners Inc. |
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19 archbiopartners.com ↗ |
| 2020-10-07 |
Arch Biopartners Inc. |
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida archbiopartners.com ↗ |
| 2020-09-10 |
Arch Biopartners Inc. |
Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide archbiopartners.com ↗ |
| 2020-08-18 |
Arch Biopartners Inc. |
Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST archbiopartners.com ↗ |
| 2020-08-07 |
Arch Biopartners Inc. |
Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST archbiopartners.com ↗ |
| 2020-08-04 |
Arch Biopartners Inc. |
Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide archbiopartners.com ↗ |
| 2020-07-28 |
Arch Biopartners Inc. |
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide archbiopartners.com ↗ |
| 2020-07-14 |
Arch Biopartners Inc. |
Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S. archbiopartners.com ↗ |
| 2020-06-16 |
Arch Biopartners Inc. |
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients archbiopartners.com ↗ |
| 2020-06-15 |
Arch Biopartners Inc. |
Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide) archbiopartners.com ↗ |
| 2020-06-08 |
Arch Biopartners Inc. |
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide) archbiopartners.com ↗ |
| 2019-11-07 |
Arch Biopartners Inc. |
Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide) archbiopartners.com ↗ |
| 2018-12-11 |
Arch Biopartners Inc. |
Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide) archbiopartners.com ↗ |
| 2018-05-08 |
Arch Biopartners Inc. |
Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients archbiopartners.com ↗ |
|